References
- Rehfeld JF, Federspiel B, Agersnap M, et al. The uncovering and characterization of a CCKoma syndrome in enteropancreatic neuroendocrine tumor patients. Scand J Gastroenterol. 2016;51:1172–1178.
- Rehfeld JF. Cholecystokinin expression in tumors: biogenetic and diagnostic implications. Future Oncol. 2016;12:2135–2147.
- Ito T, Igarashi H, Jensen RT. Pancreatic neuroendocrine tumors: clinical features, diagnosis and medical treatment: advances. Best Pract Res Clin Gastroenterol. 2012;26:737–753.
- Bläker M, Arrenberg P, Stange I, et al. The cholecystokinin2-receptor mediates calcitonin secretion, gene expression, and proliferation in the human medullary thyroid carcinoma cell line, TT. Regul Pept. 2004;118:111–117.
- Gray TK, Brannan P, Juan D, et al. Ion transport changes during calcitonin-induced intestinal secretion in man. Gastroenterology. 1976;71:392–398.
- Reubi JC. CCK receptors in human neuroendocrine tumors: clinical implications. Scand J Clin Lab Invest Suppl. 2001;234:101–104.
- Schneider R, Waldmann J, Swaid Z, et al. Calcitonin-secreting pancreatic endocrine tumors: systematic analysis of a rare tumor entity. Pancreas. 2011;40:213–221.
- Fabian E, Kump P, Krejs GJ. Diarrhea caused by circulating agents. Gastroenterol Clin North Am. 2012;41:603–610.
- Matuchansky C, Huet PM, Mary JY, et al. Effects of cholecystokinin and metoclopramide on jejunal movements of water and electrolytes and on transit time of luminal fluid in man. Eur J Clin Invest. 1972;2:169–175.
- Morton MF, Welsh NJ, Tavares IA, et al. Pharmacological characterization of cholecystokinin receptors mediating contraction of human gallbladder and ascending colon. Regul Pept. 2002;105:59–64.